Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Haig AE"'
Autor:
Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group, Baccarani M
Publikováno v:
New England Journal of Medicine. 358:1215-1228
The primary end point was reached in 84% of patients in the mepolizumab group, as compared with 43% of patients in the placebo group (hazard ratio, 2.90; 95% confidence interval [CI], 1.59 to 5.26; P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::115ff08d425c82beffaa08248238cd27
https://doi.org/10.1056/nejmoa070812
https://doi.org/10.1056/nejmoa070812
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Roufosse FE; Department of Internal Medicine, Hôpital Erasme, Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium., Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD
Publikováno v:
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2013 Feb; Vol. 131 (2), pp. 461-7.e1-5. Date of Electronic Publication: 2012 Oct 04.
Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone.
Autor:
Ellis CN; Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA., Barker JN, Haig AE, Parker CA, Daly S, Jayawardene DA
Publikováno v:
American journal of clinical dermatology [Am J Clin Dermatol] 2007; Vol. 8 (2), pp. 93-102.